Cargando…
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). However, the role of BRCA1/2-associated family cancer history (FCH) has remained unexplored in treating these four cancer types as a homogenous pathophysiological group. We aimed to...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755278/ https://www.ncbi.nlm.nih.gov/pubmed/33351846 http://dx.doi.org/10.1371/journal.pone.0244149 |
_version_ | 1783626325066514432 |
---|---|
author | Ishiyama, Yudai Shimbo, Masaki Iizuka, Junpei Deshpande, Gautam Tanabe, Kazunari Hattori, Kazunori |
author_facet | Ishiyama, Yudai Shimbo, Masaki Iizuka, Junpei Deshpande, Gautam Tanabe, Kazunari Hattori, Kazunori |
author_sort | Ishiyama, Yudai |
collection | PubMed |
description | In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). However, the role of BRCA1/2-associated family cancer history (FCH) has remained unexplored in treating these four cancer types as a homogenous pathophysiological group. We aimed to clarify the relationship between BRCA1/2-associated FCH and PC, and to assess its relationship with cancer aggressiveness. Patient characteristics, positive family history of BRCA1/2-associated cancer, and cancer characteristics (Gleason score, prostate specific antigen level at diagnosis, and clinical tumor stage) were analyzed. Among the 1,985 eligible candidates, 473 (23.83%) patients had adequately detailed FCH, obtained via questionnaire, and were thus included in the study. BRCA1/2-associated FCH was observed in 135 (28.54%) patients with PC (68, 14.38%), breast (44, 9.30%), pancreatic (31, 6.55%), or ovarian (8, 1.69%) cancers. BRCA1/2-associated FCH was not significantly associated with high Gleason score (≥ 8). Patients with BRCA-associated FCH were less likely to present with high clinical tumor stage, and no difference was observed in prostate-specific antigen level, presence of metastatic lesions at diagnosis, or likelihood of high-risk classification between patients with and without BRCA-associated FCH. This is the first report of BRCA1/2-associated FCH in Japanese men, indicating that family history did not affect the severity or aggressiveness of PC. |
format | Online Article Text |
id | pubmed-7755278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-77552782021-01-06 Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort Ishiyama, Yudai Shimbo, Masaki Iizuka, Junpei Deshpande, Gautam Tanabe, Kazunari Hattori, Kazunori PLoS One Research Article In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). However, the role of BRCA1/2-associated family cancer history (FCH) has remained unexplored in treating these four cancer types as a homogenous pathophysiological group. We aimed to clarify the relationship between BRCA1/2-associated FCH and PC, and to assess its relationship with cancer aggressiveness. Patient characteristics, positive family history of BRCA1/2-associated cancer, and cancer characteristics (Gleason score, prostate specific antigen level at diagnosis, and clinical tumor stage) were analyzed. Among the 1,985 eligible candidates, 473 (23.83%) patients had adequately detailed FCH, obtained via questionnaire, and were thus included in the study. BRCA1/2-associated FCH was observed in 135 (28.54%) patients with PC (68, 14.38%), breast (44, 9.30%), pancreatic (31, 6.55%), or ovarian (8, 1.69%) cancers. BRCA1/2-associated FCH was not significantly associated with high Gleason score (≥ 8). Patients with BRCA-associated FCH were less likely to present with high clinical tumor stage, and no difference was observed in prostate-specific antigen level, presence of metastatic lesions at diagnosis, or likelihood of high-risk classification between patients with and without BRCA-associated FCH. This is the first report of BRCA1/2-associated FCH in Japanese men, indicating that family history did not affect the severity or aggressiveness of PC. Public Library of Science 2020-12-22 /pmc/articles/PMC7755278/ /pubmed/33351846 http://dx.doi.org/10.1371/journal.pone.0244149 Text en © 2020 Ishiyama et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ishiyama, Yudai Shimbo, Masaki Iizuka, Junpei Deshpande, Gautam Tanabe, Kazunari Hattori, Kazunori Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort |
title | Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort |
title_full | Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort |
title_fullStr | Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort |
title_full_unstemmed | Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort |
title_short | Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort |
title_sort | association between prostate cancer characteristics and brca1/2-associated family cancer history in a japanese cohort |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755278/ https://www.ncbi.nlm.nih.gov/pubmed/33351846 http://dx.doi.org/10.1371/journal.pone.0244149 |
work_keys_str_mv | AT ishiyamayudai associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort AT shimbomasaki associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort AT iizukajunpei associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort AT deshpandegautam associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort AT tanabekazunari associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort AT hattorikazunori associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort |